Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Spiriva Respimat Tiotropium bromide Chronic obstructive pulmonary disease List with clinical criteria and/or conditions Complete
Spravato esketamine hydrochloride Major depressive disorder (MDD), adults Do not reimburse Complete
Spriafil Posaconazole Aspergillus and Candida infections Do not list Complete
Stalevo Carbidopa, levodopa and entacapone Parkinsons Disease List in a similar manner Complete
Steglatro ertugliflozin Diabetes mellitus, Type 2 Do not reimburse Complete
Stelara Ustekinumab Arthritis, psoriatic Do not list at the submitted price Complete
Stelara Ustekinumab Psoriasis List with clinical criteria and/or conditions Complete
Stelara/Stelara I.V ustekinumab Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Stelara/Stelara I.V. ustekinumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete
Stivarga Regorafenib Unresectable Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Complete